Stem Cells & The Fight Against Chronic Liver Disease

Mesenchymal stem cell (MSC) therapy has shown significant promise in treating chronic liver disorders (CLDs), particularly liver fibrosis and cirrhosis. A comprehensive review published in Annals of Translational Medicine highlights that MSCs possess regenerative properties that can ameliorate liver fibrosis and improve liver function. The study emphasizes that MSCs can differentiate into hepatocyte-like cells, secrete growth factors, and modulate the immune response, all of which contribute to liver tissue repair and regeneration.

Further supporting this, a study in Stem Cell Research & Therapy discusses the therapeutic potential of MSCs in liver diseases. The research indicates that MSCs can enhance liver function and reduce fibrosis by promoting tissue repair and modulating the immune system. Clinical trials have demonstrated that MSC infusion can improve liver function indices without significant adverse effects, suggesting a safe and effective approach for treating liver cirrhosis. 

Additionally, a recent article in Stem Cell Research & Therapy underscores the transformative potential of MSCs in liver diseases. The study reports that MSCs derived from bone marrow and umbilical cord have shown remarkable promise in reversing liver damage, improving liver function, and reducing fibrosis. These findings suggest that MSC therapy could be a game-changer in the management of liver diseases.

Collectively, these studies provide robust evidence supporting the efficacy of MSC therapy in treating liver diseases, highlighting its potential to repair damaged liver tissue, reduce fibrosis, and improve overall liver function.

Background on CLD’s

There are several contributing factors to chronic liver disorders. In many Western countries, alcoholism can lead to fatty liver disease, a type of CLD. Non-alcoholic fatty liver disease is also widespread. Virus-mediated hepatitis affects millions of people throughout the world. The biggest impact is felt in parts of Asia, Africa, and Latin America.

Historically, the ideal treatment for these disorders has involved a complete liver transplant. This has typically been an impractical solution, given the dearth of suitable donors, along with the high costs of the procedure.

Transplantation of Hepatocytes

Transplanting new hepatocytes (traditionally defined as the chief functional cells of the liver) into patients with CLDs is now a standard procedure. This involves the use of fresh cells, or cells that have been cryo-stored. These hepatocytes come from liver tissues that were rejected for transplant. The cell’s functionality is kept by cell isolation from steatotic donors.

Stem Cell-Derived Hepatocytes

Mesenchymal stem cells (MSC’s) are found in bone marrow, amniotic fluid, and the umbilical cord. These cells have proven to be effective in providing symptomatic relief to patients suffering from liver disease. MSCs can transform into hepatocyte-like cells using various growth factors.

Bone Marrow-Derived Stem Cells

Bone marrow-derived stem cells have been found to create a therapeutic effect in patients suffering from cirrhosis of the liver. Studies have shown that these hematopoietic stem cells (HSCs) fuse with mature liver cells, and transfer genetic materials that stimulate cell regeneration.

Mesenchymal Stem Cells

MSCs exist throughout the body. They are found in dental pulp, amniotic fluid, and the tissue of the liver, lungs, and the gut. The cells found in bone marrow, adipose tissue, and the umbilical cord have proven the most effective in providing symptomatic relief for patients with cirrhosis. 

Any Questions?

The RegeneVive Health & Wellness team welcomes any questions you may have about stem cell research, or the procedures we currently offer patients suffering from numerous degenerative diseases. We invite you to call us at 844-446-7827 or contact us online.